Novartis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVARTIS, and when can generic versions of NOVARTIS drugs launch?
NOVARTIS has one hundred and eighty-seven approved drugs.
There are one hundred and thirteen US patents protecting NOVARTIS drugs.
There are two thousand eight hundred and eighty-one patent family members on NOVARTIS drugs in sixty-nine countries and five hundred and thirty-eight supplementary protection certificates in nineteen countries.
Summary for Novartis
International Patents: | 2881 |
US Patents: | 113 |
Tradenames: | 155 |
Ingredients: | 139 |
NDAs: | 187 |
Drug Master File Entries: | 1 |
Patent Litigation for Novartis: | See patent lawsuits for Novartis |
PTAB Cases with Novartis as patent owner: | See PTAB cases with Novartis as patent owner |
Drugs and US Patents for Novartis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | EGATEN | triclabendazole | TABLET;ORAL | 208711-001 | Feb 13, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-001 | Jul 7, 2015 | AB | RX | Yes | No | 9,517,226 | ⤷ Subscribe | ⤷ Subscribe | |||
Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | 10,131,907 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-002 | May 24, 2019 | RX | Yes | No | 8,227,462 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novartis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | EXFORGE HCT | amlodipine besylate; hydrochlorothiazide; valsartan | TABLET;ORAL | 022314-002 | Apr 30, 2009 | 6,294,197*PED | ⤷ Subscribe |
Novartis | LOPRESSIDONE | chlorthalidone; metoprolol tartrate | CAPSULE;ORAL | 019451-001 | Dec 31, 1987 | 3,998,790 | ⤷ Subscribe |
Novartis | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059-001 | Mar 13, 2007 | 6,828,320 | ⤷ Subscribe |
Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-003 | Apr 20, 2010 | 6,004,973*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Ophthalmic Solution | 0.003% | ➤ Subscribe | 2015-12-30 |
➤ Subscribe | Tablets | 10 mg/12.5 mg/160 mg | ➤ Subscribe | 2009-10-22 |
➤ Subscribe | Tablets | 150 mg, 300 mg and 600 mg | ➤ Subscribe | 2006-05-05 |
➤ Subscribe | Tablets | 50 mg and 75 mg | ➤ Subscribe | 2014-01-07 |
➤ Subscribe | Delayed-release Tablets | 360 mg | ➤ Subscribe | 2009-02-02 |
➤ Subscribe | Tablets | 40 mg, 80 mg,160 mg | ➤ Subscribe | 2004-12-28 |
➤ Subscribe | Tablets | 60 mg and 120 mg | ➤ Subscribe | 2004-12-22 |
➤ Subscribe | Extended-release Tablets | 100 mg | ➤ Subscribe | 2005-12-30 |
➤ Subscribe | Oral Solution | 2 mg/mL | ➤ Subscribe | 2004-11-05 |
➤ Subscribe | Tablets | 0.25 mg, 0.5 mg, and 0.75 mg | ➤ Subscribe | 2013-09-30 |
➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2014-06-18 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Capsules | 0.5 mg | ➤ Subscribe | 2014-09-22 |
➤ Subscribe | Tablets | 80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mg | ➤ Subscribe | 2005-12-02 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
➤ Subscribe | Capsules | 400 mg | ➤ Subscribe | 2014-01-24 |
➤ Subscribe | Tablets | 5 mg/160 mg | ➤ Subscribe | 2007-10-22 |
➤ Subscribe | Capsules | 150 mg and 200 mg | ➤ Subscribe | 2013-01-29 |
➤ Subscribe | Tablets | 10 mg/160 mg | ➤ Subscribe | 2007-10-01 |
➤ Subscribe | Injection | 4 mg/100 mg, 100 mL vial | ➤ Subscribe | 2012-01-31 |
➤ Subscribe | Tablets | 5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 m | ➤ Subscribe | 2009-09-14 |
➤ Subscribe | Nasal Spray | 0.665 mg/ Spray | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Tablets | 125 mg, 250 mg and 500 mg | ➤ Subscribe | 2004-12-28 |
➤ Subscribe | Oral Suspension | 300 mg/5 mL | ➤ Subscribe | 2006-12-26 |
➤ Subscribe | Tablets | 12.5 mg and 25 mg | ➤ Subscribe | 2014-02-04 |
➤ Subscribe | Delayed-release Tablets | 180 mg | ➤ Subscribe | 2009-06-04 |
➤ Subscribe | Capsules | 1.5 mg, 3 mg, 4.5 mg and 6 mg | ➤ Subscribe | 2004-04-21 |
➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2011-03-14 |
➤ Subscribe | Tablets | 125 mg, 250 mg, and 500 mg | ➤ Subscribe | 2011-10-28 |
➤ Subscribe | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg | ➤ Subscribe | 2016-12-30 |
➤ Subscribe | Transdermal System Extended-release | 13.3 mg/24 hr | ➤ Subscribe | 2013-01-22 |
➤ Subscribe | Tablets | 2.5 mg, 5 mg, and 7.5 mg | ➤ Subscribe | 2014-12-10 |
➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
➤ Subscribe | Tablets | 100 mg and 400 mg | ➤ Subscribe | 2007-03-12 |
➤ Subscribe | Tablets | 320 mg/12.5 mg and 320 mg/25 mg | ➤ Subscribe | 2007-02-07 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
➤ Subscribe | Capsules | 20 mg and 40 mg | ➤ Subscribe | 2008-06-04 |
➤ Subscribe | Tablets | 5 mg/320 mg | ➤ Subscribe | 2007-11-26 |
➤ Subscribe | Injection | 0.8 mg (base) /mL | ➤ Subscribe | 2008-06-11 |
➤ Subscribe | Tablets | 10 mg/320 mg | ➤ Subscribe | 2007-11-09 |
International Patents for Novartis Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2016310494 | ⤷ Subscribe |
China | 100569238 | ⤷ Subscribe |
European Patent Office | 3495355 | ⤷ Subscribe |
Japan | 4607879 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novartis Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2269603 | 300769 | Netherlands | ⤷ Subscribe | PRODUCT NAME: EVEROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/001, 003, 004 EN 006-010 (C(2012)5347) 20120725 |
3342411 | CA 2020 00007 | Denmark | ⤷ Subscribe | PRODUCT NAME: EVEROLIMUS; REG. NO/DATE: EU/1/09/538 (K(2011)6162) 20110830 |
2929031 | CR 2021 00016 | Denmark | ⤷ Subscribe | PRODUCT NAME: INCLISIRAN; REG. NO/DATE: EU/1/20/1494 20201210 |
3351246 | LUC00138 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: EVEROLIMUS; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001-008 20120725 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.